Clinical trials: Obese Patients
Bardet-Biedl Syndrome, POMC Deficiency
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
A trial to compare the weekly and daily formulations of setmelanotide in participants with genetic defects in the melanocortin-4 receptor pathway.
- Trial name
- NCT05194124
- Testing
- Setmelanotide 2 mg, Setmelanotide 2.5 mg, Setmelanotide 3 mg
- Where
- 7 sites in United States, Canada and 4 more
- Volunteers
- 19 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Adiposity
Study on the Performance of Symmcora® Mid-term Suture Versus Novosyn® Suture in Patients Undergoing Robotic Assisted Gastric Bypass Surgery
The study is designed as a prospective, mono-centric, randomized, patient blinded comparison of unidirectional barbed suture (Symmcora® mid term, UBS) vs. a conventional suture (Novosyn®, CS).
- Trial name
- BARGASTRO (NCT05433688)
- Testing
- Robotic assisted gastric bypass surgery
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Aesculap AG
COPD (Chronic Obstructive Pulmonary Disease), Obesity Hypoventilation Syndrome (OHS)
Assessment of Breathing Pattern During NIV
COPD and OHS are respiratory conditions that disrupt normal breathing. Positive airway pressure, specifically Non-Invasive Ventilation (NIV), has been shown to improve breathing and reduce symptoms in patients with these…
- Trial name
- NCT06682286
- Testing
- NIV mask A, NIV mask B
- Where
- New Zealand
- Volunteers
- 40 people
- Sponsor
- Fisher and Paykel Healthcare
Bardet-Biedl Syndrome, POMC Deficiency Obesity
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
This is a phase 3 open-label, clinical study to evaluate the efficacy, safety and tolerability of setmelanotide over 1 year of treatment, in pediatric participants aged 2 to <6 years with obesity due to either biallelic variants…
- Conditions
- Bardet-Biedl Syndrome, POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity
- Trial name
- NCT04966741
- Testing
- Setmelanotide
- Where
- 6 sites in United States, Australia and 2 more
- Volunteers
- 12 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Impaired Glucose Tolerance, Abdominal Obesity
Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.
The purpose of this study is to evaluate the efficacy of GFT505 80mg compared with placebo in improving Oral Glucose Tolerance Test (OGTT), in patients with impaired glucose tolerance and abdominal obesity, and to assess the…
- Trial name
- NCT01275469
- Testing
- GFT505 80mg
- Where
- 20 sites in France
- Volunteers
- 47 people
- Sponsor
- Genfit
28≤BMI≤35Kg/m2
Weight Loss Effect of Akkermansia Muciniphila in Obese Patients
This study intends to study the effect of Akkermansia muciniphila on weight loss and the improvement of blood inflammation and metabolic indexes in obese patients with low Body Mass Index (BMI) through multi-center clinical…
- Trial name
- NCT06780007
- Testing
- Probiotic
- Where
- China
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Overweight and Obese Adults, Obese Patients (BMI ≥ 30 kg/m²)
Eatit's Obesity Intervention: Effects on Weight, Eating Habits and Health
Obesity is a growing public health problem in Sweden, but access to care varies depending on geographical location. Eatit´s multimodal digitally dietitian-supported lifestyle intervention offers an accessible treatment…
- Trial name
- NCT07183228
- Testing
- Lifestyle Intervention for Obesity
- Where
- Sweden
- Volunteers
- 93 people
- Sponsor
- Eatit AB
Type 2 Diabetes Mellitus
A Study to Evaluate AZP531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus
Objectives: Primary Objectives To investigate the safety and tolerability of single ascending doses of AZP- 531 in healthy volunteers.
- Trial name
- NCT02040012
- Testing
- AZP-531
- Where
- United Kingdom
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Alizé Pharma
Obesity
High Density Lipoprotein Turnover
The objective of the study is to evaluate the effect of Rimonabant 20mg in comparison to placebo, on HDL and VLDL lipoprotein kinetics, over a 12 months period.
- Trial name
- NCT00408148
- Testing
- Rimonabant
- Where
- 4 sites in Australia, Finland and 2 more
- Volunteers
- 64 people
- Sponsor
- Sanofi
Obesity
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU)…
- Trial name
- NCT00603291
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 604 people
- Sponsor
- Eisai Inc.
Obesity, Dyslipidemias
European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia
Primary : To determine the effect of Rimonabant 20 mg on changes in, HDL-Cholesterol (HDL-C), triglyceride levels over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with…
- Trial name
- ETERNAL (NCT00412698)
- Testing
- rimonabant
- Where
- 15 sites in Czechia, Finland and 13 more
- Volunteers
- 645 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period
Primary Objectives: Main study: To assess in overweight to obese subjects and type 2 diabetes mellitus (T2DM) patients not requiring anti-diabetic pharmacotherapy the safety and tolerability of 3 different dose escalation…
- Trial name
- NCT03414736
- Testing
- SAR425899
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sanofi
Obesity, Metabolic Syndrome
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with obesity and metabolic syndrome.
- Trial name
- NCT05891834
- Testing
- INV-202
- Where
- 24 sites in Canada
- Volunteers
- 243 people
- Sponsor
- Inversago Pharma Inc.
Hypertension
Obese Hypertension Study (0954-315)
This is a 16-week study to evaluate high systolic and diastolic blood pressure following treatment in obese, hypertensive, adult patients.
- Trial name
- NCT00289887
- Testing
- Comparator: losartan +/- HCTZ
- Volunteers
- 261 people
- Sponsor
- Organon and Co
Hypertension, Diabetes Mellitus, Type 2
SMOOTH - Blood Pressure Control in Diabetic/Obese Patients
The primary objective of this study is to demonstrate that telmisartan 80 mg combined with hydrochlorothiazide 12.5 mg (T80/H12.5) is at least as effective and possibly superior to valsartan 160 mg combined with…
- Trial name
- NCT00239538
- Testing
- telmisartan combined with hydrochlorothiazide (80/12.5 mg), valsartan combined with hydrochlorothiazide (160/12.5mg)
- Where
- 102 sites in United States, Argentina and 6 more
- Volunteers
- 840 people
- Sponsor
- Boehringer Ingelheim
Obesity
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate.
- Trial name
- NCT04667377
- Testing
- BI 456906
- Where
- 43 sites in United States, Australia and 10 more
- Volunteers
- 387 people
- Sponsor
- Boehringer Ingelheim
Overweight and Obesity
Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients
The purpose of this study is to evaluate the effects of a new daily subcutaneous (SC) injectable formulation of setmelanotide (RM-493) in healthy participants with obesity on mean percent body weight loss and other weight loss…
- Trial name
- NCT02041195
- Testing
- Setmelanotide
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity, Diabetes Mellitus, Type 2
A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet
The purpose of this study is to determine the efficacy and safety of topiramate compared with placebo in obese, Type 2 diabetic patients on a controlled diet.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231530
- Testing
- topiramate
- Volunteers
- 541 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity, Nutritional and Metabolic Diseases
A Study of the Safety of R256918 in Obese Patients
This study investigates the safety of 12 weeks of treatment with R256918, in obese patients (JNJ-16269110 and R256918 are different names for the same molecule).
- Conditions
- Obesity, Nutritional and Metabolic Diseases, Metabolic Diseases, Nutrition Disorders
- Trial name
- NCT01041677
- Testing
- R256918
- Where
- 3 sites in Finland, Netherlands and 1 more
- Volunteers
- 71 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Psoriasis, Metabolic Syndrome
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
This study was a randomized, open-label, parallel-group, active comparator controlled study with two treatment arms designed to answer the question whether the combination of Secukinumab with lifestyle intervention could…
- Trial name
- METABOLYX (NCT03440736)
- Testing
- Secukinumab, Life-style intervention
- Where
- 75 sites in Germany
- Volunteers
- 781 people
- Sponsor
- Novartis Pharmaceuticals